Neurogene
NGNE
49 hedge funds and large institutions have $386M invested in Neurogene in 2016 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 16 increasing their positions, 10 reducing their positions, and 9 closing their positions.
1,315% more call options, than puts
Call options by funds: $481K | Put options by funds: $34K
150% more funds holding in top 10
Funds holding in top 10: 2 → 5 (+3)
60% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 10
33% more first-time investments, than exits
New positions opened: 12 | Existing positions closed: 9
26% more capital invested
Capital invested by funds: $306M → $386M (+$80.7M)
7% more funds holding
Funds holding: 46 → 49 (+3)
5% more ownership
Funds ownership: 0% → 5% (+5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.35M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$1.9M |
| 3 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$1.34M |
| 4 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
+$1.32M |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$4.54M |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$719K |
| 3 |
Franklin Resources
San Mateo,
California
|
-$531K |
| 4 |
VKH
Virtu KCG Holdings
New York
|
-$438K |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$336K |
NGNE Hedge Fund Activity: Q4 2016 in Review
49 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q4 2016, worth a combined $386M — up 26% from $306M a quarter earlier.
Buyers outnumbered sellers: 12 funds opened new NGNE positions and 9 closed out — a net gain of 3 holders — while 16 added to existing stakes and 10 trimmed.
The largest buyer was Eventide Asset Management, opening a new position worth an estimated $2.35M. The largest seller was Nexthera Capital, exiting entirely with an estimated $4.54M sold.
- 49 institutional investors held Neurogene (NGNE) as of Q4 2016, up from 46 in Q3 2016.
- Funds reported $386M of Neurogene stock for Q4 2016, up 26% quarter-over-quarter.
- 12 funds opened new Neurogene positions in Q4 2016 and 9 closed out, a net change of +3 holders.
- The largest Neurogene buyer in Q4 2016 was Eventide Asset Management, an estimated $2.35M added.
- The largest Neurogene seller in Q4 2016 was Nexthera Capital, an estimated $4.54M sold.
Based on aggregated 13F filings for Q4 2016.